Genentech to more than double East Coast manufacturing plant investment to $2B

Genentech, a member of the Roche (RHHBY) Group, announced an expansion of its initial investment in a new Holly Springs, North Carolina manufacturing facility. “The increased investment will more than double the total commitment for the company’s first-ever East Coast manufacturing facility to approximately $2 billion. The expansion builds on the company’s May 2025 investment announcement, as well as the project’s August 2025 groundbreaking, and reflects Genentech’s continued confidence in the region’s community, workforce, and long-term growth potential. The expanded investment allows Genentech to build out additional production capacity and significantly increase the facility’s output. Set to be operational by 2029, the state-of-the-art facility will produce next-generation treatments for metabolic conditions, such as obesity. By leveraging advanced biomanufacturing, automation, and digital tools, the investment will boost efficiency and sustainability while significantly expanding Genentech’s U.S.-based supply chain. The expanded investment is expected to add an additional 100 new jobs to the North Carolina economy, with the project supporting more than 500 high-wage manufacturing jobs and 1,500 construction jobs, reinforcing Genentech’s role as a significant economic driver,” the company stated.